Forced Degradation and Stability Analysis of a Fixed-Dose Combination for Tuberculosis in HIV Patients

Authors

  • Rathinasamy M
  • Senthilkumar Palaniappan

Keywords:

Tuberculosis, Fixed-Dose Combination, Forced Degradation, Stability Study, RP-HPLC, Isoniazid, Sulfamethoxazole, Trimethoprim, Pyridoxine Hydrochloride

Abstract

Tuberculosis (TB) remains a major health challenge, particularly among HIV-infected individuals, due to their compromised immune systems. This study aimed to develop and evaluate a Fixed-Dose Combination (FDC) of Sulfamethoxazole, Trimethoprim, Isoniazid, and Pyridoxine Hydrochloride for the treatment of secondary TB in HIV patients. The study involved forced degradation, stability analysis, and validation of an RP-HPLC method for simultaneous quantification of the active pharmaceutical ingredients (APIs). The forced degradation study revealed that the FDC formulation degraded significantly in acidic (0.1N HCl) and oxidative (3% H₂O₂) conditions, while it remained stable under thermal (70°C dry heat) and photolytic (UV 254 nm) conditions. The stability study, conducted under accelerated (40°C, 75% RH) and intermediate (30°C, 75% RH) conditions over 24 months, demonstrated that the FDC maintained physical integrity, dissolution efficiency (NLT 75% within 60 minutes), and assay compliance (90-110% of labeled claims). The HPLC method validation confirmed high accuracy, precision, linearity, specificity, and robustness in detecting all four drugs simultaneously. These findings suggest that this FDC formulation is stable, bioavailable, and suitable for clinical use in TB-HIV co-infected patients. Further clinical trials are recommended to validate therapeutic efficacy in human subjects

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

References

Hamada Y, Getahun H, Tadesse BT, Ford N. HIV-associated tuberculosis. Int J STD AIDS. 2021 Aug;32(9):780-790. doi: 10.1177/0956462421992257. Epub 2021 Feb 20. PMID: 33612015; PMCID: PMC8236666.

Blomberg B, Fourie B. Fixed-dose combination drugs for tuberculosis: application in standardised treatment regimens. Drugs. 2003;63(6):535-53. doi: 10.2165/00003495-200363060-00002. PMID: 12656652.

Sotgiu G, Centis R, D'ambrosio L, Migliori GB. Tuberculosis treatment and drug regimens. Cold Spring Harb Perspect Med. 2015 Jan 8;5(5):a017822. doi: 10.1101/cshperspect.a017822. PMID: 25573773; PMCID: PMC4448591.

Sibanda EL, Weller IV, Hakim JG, Cowan FM. Does trimethoprim-sulfamethoxazole prophylaxis for HIV induce bacterial resistance to other antibiotic classes? Results of a systematic review. Clin Infect Dis. 2011 May;52(9):1184-94. doi: 10.1093/cid/cir067. PMID: 21467024; PMCID: PMC3070868.

Sankar J, Chauhan A, Singh R, Mahajan D. Isoniazid-historical development, metabolism associated toxicity and a perspective on its pharmacological improvement. Front Pharmacol. 2024 Sep 19;15:1441147. doi: 10.3389/fphar.2024.1441147. PMID: 39364056; PMCID: PMC11447295.

Semvua HH, Kibiki GS. AtriplaR/anti-TB combination in TB/HIV patients. Drug in focus. BMC Res Notes. 2011 Nov 24;4:511. doi: 10.1186/1756-0500-4-511. PMID: 22114934; PMCID: PMC3236078.

Gallardo CR, Rigau Comas D, Valderrama Rodríguez A, Roqué i Figuls M, Parker LA, Caylà J, Bonfill Cosp X. Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis. Cochrane Database Syst Rev. 2016 May 17;2016(5):CD009913. doi: 10.1002/14651858.CD009913.pub2. PMID: 27186634; PMCID: PMC4916937.

Healthy New Zealand white rabbits (2.5–3 kg) were procured from a certified animal supplier and housed in a controlled environment with a temperature of 22 ± 2°C, humidity of 50 ± 10%, and a 12-hour light/dark cycle. The rabbits were acclimatized for one week before the start of the experiment. The study protocol was approved by the institutional animal ethics committee.

The animals were fasted overnight before oral administration of drugs, with free access to water. Drug doses were calculated based on human therapeutic doses and adjusted according to body weight. The rabbits were divided into six groups, each containing three animals, to evaluate the pharmacokinetics of individual drugs and the FDC.

Caldeira C, Freitas JC, Gimenes I, Silva SA, Cabello P, Presgrave OA. Normal temperature variation in New Zealand white rabbits during restraint for preliminary pyrogen test. Pharmeur Bio Sci Notes. 2014;2014:118-23. PMID: 25655248.

Parasuraman S, Raveendran R, Kesavan R. Blood sample collection in small laboratory animals. J Pharmacol Pharmacother. 2010 Jul;1(2):87-93. doi: 10.4103/0976-500X.72350. Erratum in: J Pharmacol Pharmacother. 2017 Jul-Sep;8(3):153. doi: 10.4103/0976-500X.215702. PMID: 21350616; PMCID: PMC3043327.

Sayar E, Sahin S, Cevheroglu S, Hincal AA. Development and validation of an HPLC method for simultaneous determination of trimethoprim and sulfamethoxazole in human plasma. Eur J Drug Metab Pharmacokinet. 2010 Sep;35(1-2):41-6. doi: 10.1007/s13318-010-0006-9. PMID: 21495265.

Rønn AM, Mutabingwa TK, Kreisby S, Angelo HR, Fuursted K, Bygbjerg IC. A reversed-phase high-performance liquid chromatography method for the determination of cotrimoxazole (trimethoprim/ sulphamethoxazole) in children treated for malaria. Ther Drug Monit. 1999 Dec;21(6):609-14. doi: 10.1097/00007691-199912000-00005. PMID: 10604820.

Veeran MG, C K, B B, Painuly D, Aprem AS. RP-HPLC method validation for fast extraction and quantification of Levonorgestrel drug from silicone based intrauterine device intended for in-process and finished formulation. Daru. 2021 Jun;29(1):185-193. doi: 10.1007/s40199-021-00396-7. Epub 2021 May 1. PMID: 33934266; PMCID: PMC8149566.

K M P, C B, Sola P, Ansary A, Kumar Das T, Pasha TY, Dutta KN, B R, Majumder M. Development of a gradient method for sulfamethoxazole, trimethoprim, isoniazid, and pyridoxine hydrochloride in rabbit plasma through QbD-driven investigation. Sci Rep. 2024 Oct 28;14(1):25806. doi: 10.1038/s41598-024-77062-w. PMID: 39468294; PMCID: PMC11519944.

Bakshi M, Singh S. HPLC and LC-MS studies on stress degradation behaviour of tinidazole and development of a validated specific stability-indicating HPLC assay method. J Pharm Biomed Anal. 2004 Jan 27;34(1):11-8. doi: 10.1016/j.japna.2003.08.003. PMID: 14738914.

Flieger J, Flieger W, Baj J, Maciejewski R. Antioxidants: Classification, Natural Sources, Activity/Capacity Measurements, and Usefulness for the Synthesis of Nanoparticles. Materials (Basel). 2021 Jul 25;14(15):4135. doi: 10.3390/ma14154135. PMID: 34361329; PMCID: PMC8347950.

Parvin N, Joo SW, Mandal TK. Enhancing Vaccine Efficacy and Stability: A Review of the Utilization of Nanoparticles in mRNA Vaccines. Biomolecules. 2024 Aug 20;14(8):1036. doi: 10.3390/biom14081036. PMID: 39199422; PMCID: PMC11353004.

Downloads

Published

2025-04-26

How to Cite

1.
Rathinasamy M RM, Palaniappan S. Forced Degradation and Stability Analysis of a Fixed-Dose Combination for Tuberculosis in HIV Patients. J Neonatal Surg [Internet]. 2025Apr.26 [cited 2025Sep.21];14(7):9-16. Available from: https://jneonatalsurg.com/index.php/jns/article/view/4437

Issue

Vol. 14 No. 7 (2025): Journal of Neonatal Surgery

Section

Original Article

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

  • Adapt — remix, transform, and build upon the material for any purpose, even commercially.

Terms:

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.